Boston Scientific has received approval to sell its Taxus Liberte paclitaxel-eluting coronary stent system in Canada.
The Natick, Mass.-based company said that Health Canada's Therapeutic Products Directorate, the authority that regulates pharmaceutical drugs and medical devices, has approved its use.
Boston Scientific said it plans to launch the product immediately in Canada.
The Taxus Liberte stent has previously been approved for sale in Europe and other international markets and is currently awaiting approval by the FDA. Therefore, it is not available for sale in the U.S.